InterveXion Therapeutics
http://intervexion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From InterveXion Therapeutics
ForMor Challenges FDA On Own-Label Supplement GMP Stance
ForMor contests a warning letter from FDA stating that as an own-label distributor, the firm is subject to both packager and labeler GMP requirements. The firm says it is only a “holder” of finished products and FDA bases its warning on the GMP rule preamble, not the actual rule.
ForMor Challenges FDA On Own-Label Supplement GMP Stance
ForMor contests a warning letter from FDA stating that as an own-label distributor, the firm is subject to both packager and labeler GMP requirements. The firm says it is only a “holder” of finished products and FDA bases its warning on the GMP rule preamble, not the actual rule.
Deals Shaping the Medical Industry (12/06)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Selected Start-Ups (7/05)
In Vivo briefly summarizes the technologies of these recently founded companies: Aeres, Azaya Therapeutics, Cellular Dynamics International, Esprit Pharma, InterveXion Therapeutics and Knopp Neurosciences.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice